Edwards Lifesciences Executive and Leadership Team

Gerianne Sarte, the Senior Vice President, Business Unit Chief Financial Officer - Surgical at Edwards Lifesciences, directs all financial planning and analysis for the surgical business unit. Managing complex budgetary frameworks, the Senior Vice President, Business Unit Chief Financial Officer - Surgical ensures fiscal discipline across research and development pipelines. This leadership role involves aligning capital allocation with long-term growth objectives for structural heart therapies. By monitoring global market trends, Gerianne Sarte optimizes resource distribution to support clinical research initiatives. The Senior Vice President, Business Unit Chief Financial Officer - Surgical maintains rigorous oversight of operational costs, ensuring the business unit achieves sustainable profitability while delivering life-changing medical technologies. Through precise financial modeling, the Senior Vice President, Business Unit Chief Financial Officer - Surgical facilitates strategic decision-making that strengthens the competitive position of the surgical division within the broader cardiovascular healthcare landscape.

Miyuki Ogushi, the Representative Executive Officer and President and at Edwards Lifesciences, directs regional operations and organizational governance. Overseeing the implementation of corporate policies, the Representative Executive Officer and President and ensures operational excellence across key markets. This leadership role involves fostering close collaboration with healthcare professionals to advance structural heart therapies. By managing complex regulatory environments, Miyuki Ogushi supports the delivery of innovative medical solutions to patients. The Representative Executive Officer and President and coordinates with global leadership to maintain high standards of clinical research and product quality. Through effective management of regional teams, the Representative Executive Officer and President and drives the adoption of advanced cardiovascular technologies. This focus on regional growth and stakeholder engagement ensures the organization remains responsive to the evolving needs of the medical community while upholding the core mission of improving patient outcomes through specialized heart valve treatments.

Geoffrey Crowley, the President at Edwards Lifesciences, oversees the execution of core business strategies and operational performance. Managing the integration of clinical research with commercial objectives, the President ensures the successful deployment of structural heart technologies. This leadership role involves driving organizational efficiency and fostering a culture of innovation. By collaborating with cross-functional teams, Geoffrey Crowley aligns product development with the specific needs of healthcare professionals. The President maintains a focus on scaling operations to meet the growing demand for advanced cardiovascular monitoring and treatment solutions. Through strategic oversight of market initiatives, the President supports the expansion of the company's footprint in critical care sectors. This commitment to operational excellence allows the organization to deliver life-changing therapies consistently. By prioritizing patient outcomes and technological advancement, the President secures the long-term viability and market impact of the company's diverse medical technology portfolio.

Donald Bobo, the Corporate Vice President, Strategy & Corporate Development at Edwards Lifesciences, architects the long-term growth roadmap for the organization. Overseeing global expansion initiatives, the Corporate Vice President, Strategy & Corporate Development identifies emerging opportunities in structural heart disease treatment. This leadership role involves evaluating potential partnerships and acquisitions that enhance the portfolio of medical technologies. By analyzing clinical research data, Donald Bobo ensures strategic alignment with the mission of improving patient outcomes. The Corporate Vice President, Strategy & Corporate Development collaborates with the Board to refine corporate objectives and market positioning. Through rigorous assessment of cardiovascular health trends, the Corporate Vice President, Strategy & Corporate Development drives the execution of high-impact business strategies. This focus on innovation and market expansion allows the organization to maintain a leadership position in the medical technology sector while addressing critical patient needs across diverse international markets.

Daveen Chopra, the Corporate Vice President, Surgical Structural Heart at Edwards Lifesciences, directs the development and commercialization of surgical heart valve therapies. Overseeing the entire product lifecycle, the Corporate Vice President, Surgical Structural Heart ensures that clinical research translates into effective patient solutions. This leadership role involves managing global teams dedicated to advancing surgical interventions for structural heart disease. By collaborating with surgeons and medical researchers, Daveen Chopra refines the design and application of life-changing cardiovascular technologies. The Corporate Vice President, Surgical Structural Heart monitors market performance and clinical outcomes to drive continuous improvement in product efficacy. Through strategic focus on surgical innovation, the Corporate Vice President, Surgical Structural Heart expands the reach of advanced therapies to patients worldwide. This commitment to excellence in structural heart care supports the company's mission of addressing serious cardiovascular conditions through high-quality, evidence-based medical devices and surgical support systems.

Joseph Nuzzolese, the Corporate Vice President, Global Supply Chain & Quality at Edwards Lifesciences, architects the logistics and manufacturing standards for the entire organization. Overseeing the integrity of the global supply chain, the Corporate Vice President, Global Supply Chain & Quality ensures the consistent availability of critical medical technologies. This leadership role involves implementing rigorous quality control protocols to meet international regulatory requirements. By optimizing manufacturing processes, Joseph Nuzzolese enhances operational efficiency and reduces lead times for life-changing therapies. The Corporate Vice President, Global Supply Chain & Quality collaborates with production teams to maintain high standards of safety and reliability. Through strategic management of global distribution networks, the Corporate Vice President, Global Supply Chain & Quality supports the company's ability to serve healthcare professionals and patients across diverse regions. This focus on supply chain resilience and quality assurance remains essential to the company's mission of delivering innovative solutions for structural heart disease.